Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18,149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.
Powles T, Sarwar N, Stockdale A, Sarker SJ, Boleti E, Protheroe A, Jones R, Chowdhury S, Peters J, Oades G, O'Brien T, Sullivan M, Aitchison M, Beltran L, Worth D, Smith K, Michel C, Trevisan G, Harvey-Jones E, Wimalasingham A, Sahdev A, Ackerman C, Crabb S. Powles T, et al. Among authors: jones r. JAMA Oncol. 2016 Oct 1;2(10):1303-1309. doi: 10.1001/jamaoncol.2016.1197. JAMA Oncol. 2016. PMID: 27254750 Clinical Trial.
The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López.
Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb S, Shamash J, Stockdale A, Lim L, Nathan P, Chowdury S. Powles T, et al. Among authors: jones r. Eur J Cancer. 2013 Mar;49(4):986-7. doi: 10.1016/j.ejca.2012.10.010. Epub 2012 Nov 5. Eur J Cancer. 2013. PMID: 23138000 No abstract available.
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.
Jones R, Vuky J, Elliott T, Mead G, Arranz JA, Chester J, Chowdhury S, Dudek AZ, Müller-Mattheis V, Grimm MO, Gschwend JE, Wülfing C, Albers P, Li J, Osmukhina A, Skolnik J, Hudes G. Jones R, et al. Invest New Drugs. 2013 Aug;31(4):1001-7. doi: 10.1007/s10637-013-9926-y. Epub 2013 Jan 18. Invest New Drugs. 2013. PMID: 23329066 Clinical Trial.
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK. Motzer RJ, et al. Among authors: jones r. N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989. N Engl J Med. 2013. PMID: 23964934 Free article. Clinical Trial.
A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.
Powles T, Foreshew SJ, Shamash J, Sarwar N, Crabb S, Sahdev A, Nixon J, Lim L, Pungaliya A, Foreshaw A, Davies R, Greenwood M, Wilson P, Pacey S, Galazi M, Jones R, Chowdhury S. Powles T, et al. Among authors: jones r. Eur J Cancer. 2014 Aug;50(12):2057-64. doi: 10.1016/j.ejca.2014.04.021. Epub 2014 Jun 4. Eur J Cancer. 2014. PMID: 24908540 Clinical Trial.
18,149 results
You have reached the last available page of results. Please see the User Guide for more information.